Echo IQ (ASX:EIQ) Advances Heart Failure Software Through FDA Review and Clinical Partnerships

Aditi Sarkar

12 November 2026 08:50 PM AEDT

Echo IQ (ASX:EIQ) Advances Heart Failure Software Through FDA Review and Clinical Partnerships

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Echo IQ reported an EchoSolv HF FDA 510(k) update on 12 October 2026.
The company had submitted its EchoSolv HF application to the FDA in December 2025 and issued follow-up application updates in September and October 2026.
A research collaboration with Mayo Clinic was announced on 12 June 2026.
An agreement with Mayo Clinic relating to EchoSolv HF was disclosed on 24 March 2026.

Echo IQ reported an EchoSolv HF FDA 510(k) update on 12 October 2026. That development places Echo IQ (ASX:EIQ) at an important point in its current programme, as the company connects recent commercial or financial milestones with work already underway. The latest update sits alongside several disclosed initiatives that clarify what has been achieved, which commitments are in place and where management has outlined its next priorities. The distinction between completed and planned activity remains central to the story.

The FDA Application Moves Through Review

The company had submitted its EchoSolv HF application to the FDA in December 2025 and issued follow-up application updates in September and October 2026. The detail helps establish the scale and scope of the activity rather than reducing the update to a single headline figure. It also identifies the operating setting in which the company is deploying its products, services or capital. The company has set out its current work through these disclosed milestones.

Clinical Research Adds Another Track

A research collaboration with Mayo Clinic was announced on 12 June 2026. This is a separate element of the company’s recent development record, with its own timetable and commercial context. An agreement with Mayo Clinic relating to EchoSolv HF was disclosed on 24 March 2026. Read together, these facts show how the current Business update connects with earlier delivery work and reported operating performance. The two updates concern different stages of the company’s programme.

Funding and Imaging Collaboration

Echo IQ announced a binding heads of agreement with Pro Medicus on 25 June, followed by an AUD 110 mn institutional Placement announcement on 1 July 2026. This adds another dimension to the business update without changing the terms of the principal announcement. The sequence provides context for the next announced activity.

What the Regulatory Process Requires

The principal next step remains the FDA review process for EchoSolv HF; a regulatory decision is not treated as complete. These priorities provide the forward-looking context for the developments already reported. Future disclosures will clarify progress against these commitments.

On 12 November 2026, Echo IQ shares closed at AUD 0.52, a decline of 2.80% for the session. The stock recorded a high of AUD 0.530 and a low of AUD 0.510, with 1,815,723 shares changing hands. These trading figures describe that day’s market activity.

FAQs

Q: What is the latest development?

A: Echo IQ reported an EchoSolv HF FDA 510(k) update on 12 October 2026.

Q: Which earlier update is relevant?

A: A research collaboration with Mayo Clinic was announced on 12 June 2026.

Q: What is the next focus?

A: The principal next step remains the FDA review process for EchoSolv HF; a regulatory decision is not treated as complete.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.